Research ReportsAlembic Pharma Q2 Results Review - Miss On Operating Performance: Dolat Capital
ADVERTISEMENT
Alembic Pharma Q2 Results Review - Miss On Operating Performance: Dolat Capital
The brokerage believes H2 will be better with
recovery in sales aided by ramp-up in new launches and stable price erosion in the US, recovery in domestic and RoW markets.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.